CONTEXT: The 2 main prototypes of fibroepithelial tumors of the breast include fibroadenoma and phyllodes tumor (PT). Although both tumors share some overlapping histologic features, there are significant differences in their clinical behavior and management. Phyllodes tumors have been further divided into clinically relevant subtypes, and there is more than one classification scheme for PT currently in use, suggesting a lack of consistency within different practices. Accurate differentiation between fibroadenoma and PT, as well as the grading of PT, may sometimes be challenging on preoperative core needle biopsy. Some immunohistochemical markers have been suggested to aid in the pathologic classification of these lesions. OBJECTIVE: To discuss the salient histopathologic features of fibroepithelial tumors and review the molecular pathways proposed for the initiation, progression, and metastasis of PTs. Also, to provide an update on immunohistochemical markers that may be useful in their differential diagnosis and outline the practice and experience at our institution from a pathologic perspective. DATA SOURCES: Sources included published articles from peer-reviewed journals in PubMed (US National Library of Medicine). CONCLUSIONS: Fibroepithelial tumor of the breast is a heterogenous group of lesions ranging from fibroadenoma at the benign end of the spectrum to malignant PT. There are overlapping histologic features among various subtypes, and transformation and progression to a more malignant phenotype may also occur. Given the significant clinical differences within various subtypes, accurate pathologic classification is important for appropriate management. Although some immunohistochemical markers may be useful in this differential diagnosis, histomorphology still remains the gold standard.
CONTEXT: The 2 main prototypes of fibroepithelial tumors of the breast include fibroadenoma and phyllodestumor (PT). Although both tumors share some overlapping histologic features, there are significant differences in their clinical behavior and management. Phyllodestumors have been further divided into clinically relevant subtypes, and there is more than one classification scheme for PT currently in use, suggesting a lack of consistency within different practices. Accurate differentiation between fibroadenoma and PT, as well as the grading of PT, may sometimes be challenging on preoperative core needle biopsy. Some immunohistochemical markers have been suggested to aid in the pathologic classification of these lesions. OBJECTIVE: To discuss the salient histopathologic features of fibroepithelial tumors and review the molecular pathways proposed for the initiation, progression, and metastasis of PTs. Also, to provide an update on immunohistochemical markers that may be useful in their differential diagnosis and outline the practice and experience at our institution from a pathologic perspective. DATA SOURCES: Sources included published articles from peer-reviewed journals in PubMed (US National Library of Medicine). CONCLUSIONS:Fibroepithelial tumor of the breast is a heterogenous group of lesions ranging from fibroadenoma at the benign end of the spectrum to malignant PT. There are overlapping histologic features among various subtypes, and transformation and progression to a more malignant phenotype may also occur. Given the significant clinical differences within various subtypes, accurate pathologic classification is important for appropriate management. Although some immunohistochemical markers may be useful in this differential diagnosis, histomorphology still remains the gold standard.
Authors: Melissa Anne Mallory; Sona A Chikarmane; Sughra Raza; Susan Lester; Stephanie A Caterson; Mehra Golshan Journal: Am Surg Date: 2015-05 Impact factor: 0.688
Authors: Andi K Cani; Daniel H Hovelson; Andrew S McDaniel; Seth Sadis; Michaela J Haller; Venkata Yadati; Anmol M Amin; Jarred Bratley; Santhoshi Bandla; Paul D Williams; Kate Rhodes; Chia-Jen Liu; Michael J Quist; Daniel R Rhodes; Catherine S Grasso; Celina G Kleer; Scott A Tomlins Journal: Mol Cancer Res Date: 2015-01-15 Impact factor: 5.852
Authors: Benjamin Y Tan; Geza Acs; Sophia K Apple; Sunil Badve; Ira J Bleiweiss; Edi Brogi; José P Calvo; David J Dabbs; Ian O Ellis; Vincenzo Eusebi; Gelareh Farshid; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Emad A Rakha; Jorge S Reis-Filho; Andrea L Richardson; Aysegul Sahin; Fernando C Schmitt; Stuart J Schnitt; Kalliopi P Siziopikou; Fernando A Soares; Gary M Tse; Anne Vincent-Salomon; Puay Hoon Tan Journal: Histopathology Date: 2016-01 Impact factor: 5.087
Authors: M Yoshida; S Sekine; R Ogawa; H Yoshida; A Maeshima; Y Kanai; T Kinoshita; A Ochiai Journal: Br J Cancer Date: 2015-04-02 Impact factor: 7.640
Authors: Christoph J Rageth; Elizabeth Am O'Flynn; Christopher Comstock; Claudia Kurtz; Rahel Kubik; Helmut Madjar; Domenico Lepori; Gert Kampmann; Alexander Mundinger; Astrid Baege; Thomas Decker; Stefanie Hosch; Christoph Tausch; Jean-François Delaloye; Elisabeth Morris; Zsuzsanna Varga Journal: Breast Cancer Res Treat Date: 2016-08-13 Impact factor: 4.872